Avalo Therapeutics (AVTX)

• Market cap: $47.1M
• 1 day: -4.75%
• 5 days: -12.50%
• 1 month: -42.65%
• 3 months: -34.67%
• 6 months: -57.60%
• Year to date: -47.69%
• 1 year: -67.62%
• 5 years: -99.95%
• 10 years: -99.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

14% more funds holding

Funds holding: 29 [Q3] → 33 (+4) [Q4]

3.37% more ownership

Funds ownership: 68.63% [Q3] → 71.99% (+3.37%) [Q4]

11% less capital invested

Capital invested by funds: $63.2M [Q3] → $56M (-$7.25M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $23 422% upside
• Avg. target: $36 709% upside
• High target: $48 988% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Kambiz Yazdi 25% 1-year accuracy 1 / 4 met price target	422% upside $23	Buy Initiated	25 Mar 2025
Stifel Alex Thompson 43% 1-year accuracy 3 / 7 met price target	716% upside $36	Buy Initiated	25 Mar 2025
Piper Sandler Yasmeen Rahimi 22% 1-year accuracy 5 / 23 met price target	988% upside $48	Overweight Initiated	28 Feb 2025